Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma

Brentuximab vedotin (BV) is an antibody-drug conjugate composed of an anti-CD30 monoclonal antibody conjugated to microtubule-disrupting agent monomethyl auristatin E (MMAE) and is indicated in the treatment of cutaneous T-cell lymphomas (CTCL).1 The most widely reported side effect associated with BV therapy is peripheral neuropathy, affecting 67% of the patients.2 This report highlights a case of grade 3 hand-foot syndrome (HFS) developing in a patient with CTCL treated with BV.